Pacira
Biotechnology
Overview
Better is possible. Join us in reimagining pain management with innovative, non-opioid therapies for chronic, postsurgical and musculoskeletal pain.
Funding and backers
Team
51-200
employees, estimated range
Backers
1
High-Tech Gründerfonds
Momentum
15/100
in the news
Last sign of life
1 mo ago
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Oct 2026
Formerly GQ Bio Therapeutics (gq-biotx.com)
Jul 2007
Website went live first capture in the Wayback Machine
Backed byfrom the funds' portfolios and accelerator catalogs
Investors in similar startupsfunds that back the companies most like this one
backs Vori Health
backs Draupnir Bio
Similar startupsby what they do, their industry and backers
Revolutionizing acute pain management. Rebel is focused on developing disruptive, non-opioid solutions for acute pain.
Bahto Biosciences develops a non-opioid small-molecule therapeutic for painful peripheral neuropathy.
Vori Health is a New York healthcare company founded in 2019 that treats musculoskeletal pain without unnecessary surgery. Its virtual…
Neurolieve Biosciences is developing NLV-01, a first-in-class, non-opioid biologic designed to silence neuropathic pain and trigger…
Draupnir Bio is developing new innovative therapies for patients.
Solving unmet needs with a proven track record. We’re a dynamic company led by experienced leaders in the industry who are strategically…
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
High-Tech GründerfondsVia a fund
517 portfolio companies
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely
News
Pacira BioSciences stock falls 2.35 percent to USD 24.11
Pacira BioSciences stock closed at USD 24.11 on September 21, 2026, down 2.35 percent from the prior close. Market value stood at USD 961.07 million.
Read more
Report
Is Pacira BioSciences (PCRX) Quietly Reframing Its Non-Opioid Strategy Around PCRX-201 Gene Therapy?
In early August 2026, Pacira BioSciences reported positive two-year Phase 1 data for its investigational gene therapy PCRX-201 for moderate-to-severe knee osteoarthritis, showing it was well tolerated with exploratory improvements in pain, stiffness, and
Read more
Report
Pacira Q2 Earnings & Revenues Beat, 2026 Sales Outlook Cut
Detailed price information for Pacira Pharm Inc (PCRX-Q) from The Globe and Mail including charting and trades.
Read more
Report
Pacira outlines $735M-$760M 2026 revenue guidance while targeting 160M EXPAREL covered lives
Read more
Report
Pacira Earnings Call Highlights Growth, Pipeline Momentum
Detailed price information for Pacira Pharm Inc (PCRX-Q) from The Globe and Mail including charting and trades.
Read more
Report
Pacira BioSciences' CFO Sold 12,941 Shares for $326,000 Before Its Q1 Earnings Release
Pacira BioSciences, a leader in non-opioid pain management, reported a notable insider sale amid ongoing option exercise activity.
Read more
Report
Report
Pacira Announces Updates to Board of Directors
-- Accomplished Business and Financial Leader, Laura Brege, Appointed Chair -- -- Paul J. Hastings and Andreas Wicki, PhD Retire from Board of Directors -- PARSIPPANY, N.J., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the in
Read more
Report
Offices
Where the company hires and what each office is for
Cities
2
Hiring now
0
Countries
1
Loading the map
Headquarters
Builds here
Office with open vacancies
No open vacancies right now Tap a pin for the office
Hamburg
Germany
HQ
Hamburg, Germany
Germany Office Ballindamm 39 20095 Hamburg Germany
Luckenwalde
Germany
Regional office
Luckenwalde, Germany
Luckenwalde Research & Development Site Im Biotechnologiepark 7 14943 Luckenwalde Germany